Mirae Asset Global Investments
SRPT icon

Mirae Asset Global Investments’s Sarepta Therapeutics SRPT Stock Holding History

Mirae Asset Global Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.9K Sell
4,722
-744
-14% -$14.1K ﹤0.01% 1272
2026
Q1 		$119K Buy
5,466
+374
+7% +$7.24K ﹤0.01% 1152
2025
Q4 		$110K Buy
5,092
+1,068
+27% +$22.5K ﹤0.01% 1243
2025
Q3 		$77.5K Sell
4,024
-18
-0.4% -$321 ﹤0.01% 1267
2025
Q2 		$69.1K Buy
4,042
+819
+25% +$34.9K ﹤0.01% 1204
2025
Q1 		$227K Sell
3,223
-3,347
-51% -$352K ﹤0.01% 1029
2024
Q4 		$797K Buy
6,570
+568
+9% +$69.6K ﹤0.01% 865
2024
Q3 		$747K Buy
6,002
+3,180
+113% +$440K ﹤0.01% 879
2024
Q2 		$446K Sell
2,822
-88,123
-97% -$11.3M ﹤0.01% 936
2024
Q1 		$12.1M Buy
90,945
+47,895
+111% +$5.87M 0.03% 558
2023
Q4 		$4.15M Sell
43,050
-52,815
-55% -$5.07M 0.01% 940
2023
Q3 		$11.6M Buy
95,865
+4,763
+5% +$538K 0.03% 559
2023
Q2 		$10.4M Sell
91,102
-1,361
-1% -$175K 0.02% 628
2023
Q1 		$12.7M Buy
92,463
+4,080
+5% +$529K 0.03% 540
2022
Q4 		$11.5M Sell
88,383
-37,147
-30% -$4.3M 0.03% 551
2022
Q3 		$13.9M Buy
125,530
+11,908
+10% +$1.2M 0.04% 453
2022
Q2 		$8.52M Sell
113,622
-19,781
-15% -$1.46M 0.02% 658
2022
Q1 		$10.4M Sell
133,403
-21,768
-14% -$1.67M 0.02% 657
2021
Q4 		$14M Sell
155,171
-20,226
-12% -$1.73M 0.03% 573
2021
Q3 		$16.2M Buy
175,397
+33,424
+24% +$2.57M 0.04% 464
2021
Q2 		$11M Buy
141,973
+85,670
+152% +$6.49M 0.03% 590
2021
Q1 		$4.2M Buy
56,303
+24,143
+75% +$2.23M 0.01% 767
2020
Q4 		$5.48M Buy
32,160
+8,724
+37% +$1.29M 0.02% 631
2020
Q3 		$3.29M Buy
23,436
+6,092
+35% +$926K 0.02% 636
2020
Q2 		$2.78M Buy
17,344
+2,046
+13% +$278K 0.02% 624
2020
Q1 		$1.5M Buy
15,298
+2,400
+19% +$274K 0.01% 721
2019
Q4 		$1.66M Buy
12,898
+3,838
+42% +$387K 0.01% 794
2019
Q3 		$682K Buy
9,060
+3,286
+57% +$388K ﹤0.01% 1059
2019
Q2 		$877K Buy
5,774
+1,579
+38% +$192K 0.01% 954
2019
Q1 		$500K Buy
+4,195
New +$539K ﹤0.01% 1042

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mirae Asset Global Investments's SRPT Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Sarepta Therapeutics (SRPT) stake by 14% in Q2 2026, selling an estimated $14.1K and leaving 4,722 shares worth $84.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1272.

Mirae Asset Global Investments first reported a position in SRPT in Q1 2019 and has held it in 30 quarters since. The position peaked at $16.2M in Q3 2021. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Mirae Asset Global Investments held 4,722 shares of Sarepta Therapeutics worth $84.9K as of Q2 2026.
  • Mirae Asset Global Investments sold 744 Sarepta Therapeutics shares in Q2 2026, an estimated $14.1K.
  • Sarepta Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1272 holding.
  • Mirae Asset Global Investments first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Mirae Asset Global Investments's Sarepta Therapeutics position peaked at $16.2M in Q3 2021.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.